51
|
Mills KA, Quinn JM, Roach ST, Palisoul M, Nguyen M, Noia H, Guo L, Fazal J, Mutch DG, Wickline SA, Pan H, Fuh KC. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. Sci Rep 2019; 9:4762. [PMID: 30886159 PMCID: PMC6423014 DOI: 10.1038/s41598-019-41122-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 02/26/2019] [Indexed: 12/16/2022] Open
Abstract
Ovarian and uterine serous cancers are extremely lethal diseases that often present at an advanced stage. The late-stage diagnosis of these patients results in the metastasis of their cancers throughout the peritoneal cavity leading to death. Improving survival for these patients will require identifying therapeutic targets, strategies to target them, and means to deliver therapies to the tumors. One therapeutic target is the protein AXL, which has been shown to be involved in metastasis in both ovarian and uterine cancer. An effective way to target AXL is to silence its expression with small interfering RNA (siRNA). We investigate the ability of the novel siRNA delivery platform, p5RHH, to deliver anti-AXL siRNA (siAXL) to tumor cells both in vitro and in vivo as well as examine the phenotypic effects of this siRNA interference. First, we present in vitro assays showing p5RHH-siAXL treatment reduces invasion and migration ability of ovarian and uterine cancer cells. Second, we show p5RHH nanoparticles target to tumor cells in vivo. Finally, we demonstrate p5RHH-siAXL treatment reduces metastasis in a uterine cancer mouse xenograft model, without causing an obvious toxicity. Collectively, these findings suggest that this novel therapy shows promise in the treatment of ovarian and uterine cancer patients.
Collapse
Affiliation(s)
- Kathryn A Mills
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - Jeanne M Quinn
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - S Tanner Roach
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - Marguerite Palisoul
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - Mai Nguyen
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - Hollie Noia
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - Lei Guo
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - Jawad Fazal
- Department of Cardiovascular Sciences, The USF Health Heart Institute, Morsani School of Medicine, University of South Florida, 4202 E. Fowler Avenue, Tampa, FL, 33620, USA
| | - David G Mutch
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO, 63110, USA
| | - Samuel A Wickline
- Department of Cardiovascular Sciences, The USF Health Heart Institute, Morsani School of Medicine, University of South Florida, 4202 E. Fowler Avenue, Tampa, FL, 33620, USA
| | - Hua Pan
- Department of Cardiovascular Sciences, The USF Health Heart Institute, Morsani School of Medicine, University of South Florida, 4202 E. Fowler Avenue, Tampa, FL, 33620, USA.
| | - Katherine C Fuh
- Center for Reproductive Health Sciences, Department of Obstetrics and Gynecology, Washington University School of Medicine, 425 S. Euclid Avenue, St. Louis, MO, 63110, USA.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO, 63110, USA.
| |
Collapse
|
52
|
Wu J, Zhao FT, Fan KJ, Zhang J, Xu BX, Wang QS, Tang TT, Wang TY. Dihydromyricetin Inhibits Inflammation of Fibroblast-Like Synoviocytes through Regulation of Nuclear Factor- κB Signaling in Rats with Collagen-Induced Arthritis. J Pharmacol Exp Ther 2018; 368:218-228. [PMID: 30530730 DOI: 10.1124/jpet.118.253369] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 11/26/2018] [Indexed: 12/15/2022] Open
Abstract
Dihydromyricetin (DMY), the main flavonoid of Ampelopsis grossedentata, has potent anti-inflammatory activity. However, the effect of DMY on chronic autoimmune arthritis remains undefined. In this study, we investigated the therapeutic effects of DMY on collagen-induced arthritis (CIA). Wistar rats were immunized with bovine type II collagen to establish CIA and were then administered DMY intraperitoneally (5, 25, and 50 mg/kg) every other day for 5 weeks. Paw swelling, clinical scoring, and histologic analysis were assessed to determine the therapeutic effects of DMY on the development of arthritis in CIA rats. The results showed that treatment with DMY significantly reduced erythema and swelling in the paws of CIA rats. Pathologic analysis of the knee joints and peripheral blood cytokine assay results confirmed the antiarthritic effects of DMY on synovitis and inflammation. Fibroblast-like synoviocytes (FLSs) were isolated from the synovium of CIA rats and treated with 10 ng/ml interleukin (IL)-1β DMY significantly inhibited the proliferation, migration, and inflammation of IL-1β-induced FLSs, whereas it significantly increased IL-1β-induced FLS apoptosis in a dose-dependent manner (6.25-25 μM). Moreover, DMY suppressed phosphorylation of IκB kinase (IKK) and inhibitor of NF-κB α and subsequently reduced the IL-1β-induced nucleus translocation of NF-κB in FLSs. Through a molecular docking assay, we demonstrated that DMY could directly bind to the Thr9 and Asp88 residues in IKKα and the Asp95, Asn142, and Gln167 residues in IKKβ These findings demonstrate that DMY could alleviate inflammation in CIA rats and attenuate IL-1β-induced activities in FLSs through suppression of NF-κB signaling.
Collapse
Affiliation(s)
- Jing Wu
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| | - Fu-Tao Zhao
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| | - Kai-Jian Fan
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| | - Jun Zhang
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| | - Bing-Xing Xu
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| | - Qi-Shan Wang
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| | - Ting-Ting Tang
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| | - Ting-Yu Wang
- Departments of Pharmacy (J.W., K.-J.F., B.-X.X., Q.-S.W., T.-Y.W.) and Rheumatology and Immunology (F.-T.Z.), and Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery (T.-T.T.), Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; and Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (J.Z.)
| |
Collapse
|
53
|
Yao Y, Yu H, Liu Y, Xu Q, Li X, Meng X, Huang C, Li J. PSTPIP2 Inhibits the Inflammatory Response and Proliferation of Fibroblast-Like Synoviocytes in vitro. Front Pharmacol 2018; 9:1432. [PMID: 30564127 PMCID: PMC6289071 DOI: 10.3389/fphar.2018.01432] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Accepted: 11/19/2018] [Indexed: 11/23/2022] Open
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease and its pathogenesis remains unclear. Fibroblast-like synoviocytes (FLSs) play an important role in the pathogenesis of RA. Proline-serine-threonine phosphatase interacting protein 2 (PSTPIP2) is an adaptor protein, which is associated with auto-inflammatory disease. In this study, we selected adjuvant-induced arthritis (AIA) as animal model to study the role of PSTPIP2 in FLSs. We found that the expression of PSTPIP2 was significantly down-regulated in synovial tissues and FLSs of AIA rat compared with normal group. And overexpression of PSTPIP2 could inhibit the proliferation and inflammatory response of FLSs. Moreover, the proliferation and inflammatory response of FLSs were promoted with PSTPIP2 silencing treatment. In terms of mechanism, we found that the expression of PSTPIP2 was closely related to NF-κB signaling pathway. Overall, our results suggested that PSTPIP2 inhibits the proliferation and inflammatory response of FLSs, which might be closely related to NF-κB signaling pathway.
Collapse
Affiliation(s)
- Yao Yao
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| | - Haixia Yu
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| | - Yaru Liu
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| | - Qingqing Xu
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| | - Xiaofeng Li
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| | - Xiaoming Meng
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| | - Cheng Huang
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| | - Jun Li
- Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China.,The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, China
| |
Collapse
|
54
|
Janakiraman K, Krishnaswami V, Rajendran V, Natesan S, Kandasamy R. Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights. MATERIALS TODAY. COMMUNICATIONS 2018; 17:200-213. [PMID: 32289062 PMCID: PMC7104012 DOI: 10.1016/j.mtcomm.2018.09.011] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 09/11/2018] [Accepted: 09/13/2018] [Indexed: 05/02/2023]
Abstract
Rheumatoid arthritis (RA) is the most common complex multifactorial joint related autoimmune inflammatory disease with unknown etiology accomplished with increased cardiovascular risks. RA is characterized by the clinical findings of synovial inflammation, autoantibody production, and cartilage/bone destruction, cardiovascular, pulmonary and skeletal disorders. Pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and IL-10 were responsible for the induction of inflammation in RA patients. Drawbacks such as poor efficacy, higher doses, frequent administration, low responsiveness, and higher cost and serious side effects were associated with the conventional dosage forms for RA treatment. Nanomedicines were recently gaining more interest towards the treatment of RA, and researchers were also focusing towards the development of various anti-inflammatory drug loaded nanoformulations with an aid to both actively/passively targeting the inflamed site to afford an effective treatment regimen for RA. Alterations in the surface area and nanoscale size of the nanoformulations elicit beneficial physical and chemical properties for better pharmacological activities. These drug loaded nanoformulations may enhances the solubility of poorly water soluble drugs, improves the bioavailability, affords targetability and may improve the therapeutic activity. In this regimen, the present review focus towards the novel nanoparticulate formulations (nanoparticles, nanoemulsions, solid lipid nanoparticles, nanomicelles, and nanocapsules) utilized for the treatment of RA. The recent advancements such as siRNA, peptide and targeted based nanoparticulate systems for RA treatment were also discussed. Special emphasis was provided regarding the pathophysiology, prevalence and symptoms towards the development of RA.
Collapse
Key Words
- A-SLN, actarit loaded solid lipid nanoparticles
- ACF-SLN, aceclofenac loaded solid lipid nanoparticles
- AIA, antigen-induced arthritis
- ALP, alkaline phosphate
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- C-SLN, curcumin loaded solid lipid nanoparticles
- CEL-TS-LN, celecoxib loaded tristearin based lipidic nanoparticles
- CFA, complete freund’s adjuvant
- CHNP, chitosan nanoparticle
- CLSM, confocal laser scanning microscopy
- COX- 1, cyclooxygenase - 1
- COX- 2, cyclooxygenase - 2
- DEX, dexamethasone
- DEX-PMs, dexamethasone-loaded polymeric micelles
- DMARD, disease modifying antirheumatic drugs
- FA, folic acid
- FR-β, folate receptor-beta
- GC, glucocorticoid
- HA- AuNP/TCZ, hyaluronate gold nanoparticle/Tocilizumab
- HEKcells, human embryonic kidney cells
- HSA-NCs, human serum albumin nanocapsules
- HUVEC, human umbilical vein cells
- IL, interleukin
- IND-NMs, indomethacin loaded polymeric micelles
- Ig, immunoglobulin
- Ind-NCs, indomethacin-loaded nanocapsules
- Inflammation
- LDE, lipidic nanoemulsion
- LX-NMs, larnoxicam loaded nanomicelles
- MTX-LCNCs, methotrexate-loaded lipidic core nanocapsules
- NSAIDs, non steroidal anti-inflammatory drugs
- Nanoformulation
- Nanoparticles
- P-SLN, piperine loaded solid lipid nanoparticle
- PCL, polycaprolactone
- PCL-PEG, poly (ethylene glycol)-block-poly (ε-caprolactone)
- PSA, polysialic acid
- PSA-PCL-CyA-NMs, polysialic acid- polycaprolactone cyclosporine A nanomicelles
- Pir-SLN, piroxicam solid lipid nanoparticles
- RA, rheumatoid arthritis
- RGD, arginine-glycine aspartic acid
- RNAi, RNA interference
- Rheumatoid arthritis
- SLN, solid lipid nanoparticles
- TAC-HSA-NPs, tacrolimus human serum albumin nanoparticle
- TAC-LCNCs, tacrolimus loaded lipidic core nanocapsules
- TNF-α, tumour necrosis factor
- VCAM-1, vascular cell adhesion molecule-1
- VEGF, vascular endothelial growth factor
- VIP, vasoactive intestinal peptide
- mRNA, messenger RNA
- shRNA, short hairpin RNA
- siRNA, small interfering RNA
Collapse
Affiliation(s)
- Kumar Janakiraman
- National Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India
| | - Venkateshwaran Krishnaswami
- National Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India
| | - Vijaya Rajendran
- National Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India
| | - Subramanian Natesan
- National Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India
| | - Ruckmani Kandasamy
- National Facility for Drug Development for Academia, Pharmaceutical and Allied Industries (NFDD), Centre for Excellence in Nanobio Translational REsearch (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli 620 024, Tamil Nadu, India
| |
Collapse
|
55
|
Pan H, Palekar RU, Hou KK, Bacon J, Yan H, Springer LE, Akk A, Yang L, Miller MJ, Pham CT, Schlesinger PH, Wickline SA. Anti-JNK2 peptide-siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice. Int J Nanomedicine 2018; 13:5187-5205. [PMID: 30233180 PMCID: PMC6135209 DOI: 10.2147/ijn.s168556] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND A direct and independent role of inflammation in atherothrombosis was recently highlighted by the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial, showing the benefit of inhibiting signaling molecules, eg, interleukins. Accordingly, we sought to devise a flexible platform for preventing the inflammatory drivers at their source to preserve plaque endothelium and mitigate procoagulant risk. METHODS p5RHH-siRNA nanoparticles were formulated through self-assembly processes. The therapeutic efficacy of p5RHH-JNK2 siRNA nanoparticles was evaluated both in vitro and in vivo. RESULTS Because JNK2 is critical to macrophage uptake of oxidized lipids through scavenger receptors that engender expression of myriad inflammatory molecules, we designed an RNA-silencing approach based on peptide-siRNA nanoparticles (p5RHH-siRNA) that localize to atherosclerotic plaques exhibiting disrupted endothelial barriers to achieve control of JNK2 expression by macrophages. After seven doses of p5RHH-JNK2 siRNA nanoparticles over 3.5 weeks in ApoE-/- mice on a Western diet, both JNK2 mRNA and protein levels were significantly decreased by 26% (P=0.044) and 42% (P=0.042), respectively. Plaque-macrophage populations were markedly depleted and NFκB and STAT3-signaling pathways inhibited by 47% (P<0.001) and 46% (P=0.004), respectively. Endothelial barrier integrity was restored (2.6-fold reduced permeability to circulating 200 nm nanoparticles in vivo, P=0.003) and thrombotic risk attenuated (200% increased clotting times to carotid artery injury, P=0.02), despite blood-cholesterol levels persistently exceeding 1,000 mg/dL. No adaptive or innate immunoresponses toward the nanoparticles were observed, and blood tests after the completion of treatment confirmed the largely nontoxic nature of this approach. CONCLUSION The ability to formulate these nanostructures rapidly and easily interchange or multiplex their oligonucleotide content represents a promising approach for controlling deleterious signaling events locally in advanced atherosclerosis.
Collapse
Affiliation(s)
- Hua Pan
- Department of Cardiovascular Sciences, USF Health, Morsani College of Medicine, The USF Health Heart Institute, University of South Florida, Tampa, FL, USA, ,
| | - Rohun U Palekar
- Department of Medicine, Washington University, St Louis, MO, USA
| | - Kirk K Hou
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - John Bacon
- Department of Medicine, Washington University, St Louis, MO, USA
| | - Huimin Yan
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - Luke E Springer
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - Antonina Akk
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - Lihua Yang
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - Mark J Miller
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - Christine Tn Pham
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - Paul H Schlesinger
- Department of Biomedical Engineering, Washington University, St Louis, MO, USA
| | - Samuel A Wickline
- Department of Cardiovascular Sciences, USF Health, Morsani College of Medicine, The USF Health Heart Institute, University of South Florida, Tampa, FL, USA, ,
| |
Collapse
|
56
|
Cystathionine-γ-lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis. Cell Mol Immunol 2018; 16:694-705. [PMID: 29844591 DOI: 10.1038/s41423-018-0037-8] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 04/15/2018] [Accepted: 04/22/2018] [Indexed: 12/16/2022] Open
Abstract
Cystathionine-γ-lyase (CSE), an enzyme associated with hydrogen sulfide (H2S) production, is an important endogenous regulator of inflammation. Jumonji domain-containing protein 3 (JMJD3) is implicated in the immune response and inflammation. Here, we investigated the potential contribution of JMJD3 to endogenous CSE-mediated inflammation in rheumatoid arthritis (RA). Upregulated CSE and JMJD3 were identified in synovial fibroblasts (SFs) from RA patients as well as in the joints of arthritic mice. Knocking down CSE augmented inflammation in IL-1β-induced SFs by increasing JMJD3 expression. In addition, CSE-/- mice with collagen-induced arthritis (CIA) developed severe joint inflammation and bone erosion. Conversely, overexpressing CSE inhibited JMJD3 expression by the transcription factor Sp-1 and was accompanied by reduced inflammation in IL-1β-treated SFs. Furthermore, JMJD3 silencing or the administration of the JMJD3 inhibitor GSK-J4 significantly decreased the inflammatory response in IL-1β-treated SFs, mainly by controlling the methylation status of H3K27me3 at the promoter of its target genes. GSK-J4 markedly attenuated the severity of arthritis in CIA mice. In conclusion, suppressing JMJD3 expression by the transcription factor Sp-1 is likely responsible for the ability of CSE to negatively modulate the inflammatory response and reduce the progression of RA.
Collapse
|
57
|
Kabir AU, Lee TJ, Pan H, Berry JC, Krchma K, Wu J, Liu F, Kang HK, Hinman K, Yang L, Hamilton S, Zhou Q, Veis DJ, Mecham RP, Wickline SA, Miller MJ, Choi K. Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis. JCI Insight 2018; 3:97349. [PMID: 29669933 DOI: 10.1172/jci.insight.97349] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Accepted: 03/20/2018] [Indexed: 01/24/2023] Open
Abstract
Angiogenesis, new blood vessel formation from preexisting vessels, is critical for solid tumor growth. As such, there have been efforts to inhibit angiogenesis as a means to obstruct tumor growth. However, antiangiogenic therapy faces major challenges to the selective targeting of tumor-associated-vessels, as current antiangiogenic targets also disrupt steady-state vessels. Here, we demonstrate that the developmentally critical transcription factor Etv2 is selectively upregulated in both human and mouse tumor-associated endothelial cells (TAECs) and is required for tumor angiogenesis. Two-photon imaging revealed that Etv2-deficient tumor-associated vasculature remained similar to that of steady-state vessels. Etv2-deficient TAECs displayed decreased Flk1 (also known as Vegfr2) expression, FLK1 activation, and proliferation. Endothelial tube formation, proliferation, and sprouting response to VEGF, but not to FGF2, was reduced in Etv2-deficient ECs. ROS activated Etv2 expression in ECs, and ROS blockade inhibited Etv2 expression in TAECs in vivo. Systemic administration of Etv2 siRNA nanoparticles potently inhibited tumor growth and angiogenesis without cardiovascular side effects. These studies highlight a link among vascular oxidative stress, Etv2 expression, and VEGF response that is critical for tumor angiogenesis. Targeting the ETV2 pathway might offer a unique opportunity for more selective antiangiogenic therapies.
Collapse
Affiliation(s)
- Ashraf Ul Kabir
- Department of Pathology and Immunology and.,Molecular and Cell Biology Program, Washington University School of Medicine, St. Louis, Missouri, USA
| | | | - Hua Pan
- Health Heart Institute, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA
| | - Jeffrey C Berry
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | | | - Jun Wu
- Department of Pathology and Immunology and
| | - Fang Liu
- Department of Pathology and Immunology and
| | - Hee-Kyoung Kang
- Department of Pharmacology, School of Medicine, Jeju National University, Jeju, South Korea
| | - Kristina Hinman
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Lihua Yang
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Samantha Hamilton
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Qingyu Zhou
- Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, Florida, USA
| | - Deborah J Veis
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Robert P Mecham
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Samuel A Wickline
- Health Heart Institute, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA
| | - Mark J Miller
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Kyunghee Choi
- Department of Pathology and Immunology and.,Molecular and Cell Biology Program, Washington University School of Medicine, St. Louis, Missouri, USA.,Graduate School of Biotechnology, Kyung Hee University, Yongin, South Korea
| |
Collapse
|
58
|
Pirmardvand Chegini S, Varshosaz J, Taymouri S. Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2018; 46:502-514. [PMID: 29661045 DOI: 10.1080/21691401.2018.1460373] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease with complex pathology characterized by inflammation of joints, devastation of the synovium, pannus formation, bones and cartilage destruction and often is associated with persistent arthritic pain, swelling, stiffness and work disability. In conventional RA therapy, because of short biological half-life, poor bioavailability, high and frequent dosing is required. Thereby, these anti-RA medications, which unable to selectively target affected zone, may cause severe side effects in extra-articular tissues. Today, nanotechnology has emerged as promising tool in the development of novel drug delivery systems for the treatment and diagnosis of intractable diseases such as RA. Active targeting in RA nanomedicine has also been introduced a successful way for facilitating specific uptake of therapeutic agents by the disease cells. In this review, it is attempted to describe various targeted drug delivery systems (localized and receptor-based) used for RA diagnosis and therapy. Then, we highlight recent developments related to various non-viral gene delivery systems for RA gene therapy.
Collapse
Affiliation(s)
- Sana Pirmardvand Chegini
- a Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre , Isfahan University of Medical Sciences , Isfahan , Iran
| | - Jaleh Varshosaz
- a Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre , Isfahan University of Medical Sciences , Isfahan , Iran
| | - Somayeh Taymouri
- a Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre , Isfahan University of Medical Sciences , Isfahan , Iran
| |
Collapse
|
59
|
Cai M, Yang L, Zhang S, Liu J, Sun Y, Wang X. A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy. Int J Nanomedicine 2017; 12:7469-7482. [PMID: 29075114 PMCID: PMC5648312 DOI: 10.2147/ijn.s139775] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
With increasing fracture risks due to fragility, osteoporosis is a global health problem threatening postmenopausal women. In these patients, osteoclasts play leading roles in bone loss and fracture. How to inhibit osteoclast activity is the key issue for osteoporosis treatment. In recent years, miRNA-based gene therapy through gene regulation has been considered a potential therapeutic method. However, in light of the side effects, the use of therapeutic miRNAs in osteoporosis treatment is still limited by the lack of tissue/cell-specific delivery systems. Here, we developed polyurethane (PU) nanomicelles modified by the acidic peptide Asp8. Our data showed that without overt toxicity or eliciting an immune response, this delivery system encapsulated and selectively deliver miRNAs to OSCAR+ osteoclasts at bone-resorption surface in vivo. With the Asp8-PU delivery system, anti-miR214 was delivered to osteoclasts, and bone microarchitecture and bone mass were improved in ovariectomized osteoporosis mice. Therefore, Asp8-PU could be a useful bone-resorption surface-targeting delivery system for treatment of osteoclast-induced bone diseases and aging-related osteoporosis.
Collapse
Affiliation(s)
- Mingxiang Cai
- Engineering Research Center of Tooth Restoration and Regeneration, Department of Oral Implantology, School of Stomatology, Tongji University, Shanghai
| | - Li Yang
- Department of Cell Biology, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China
| | - Shufan Zhang
- Engineering Research Center of Tooth Restoration and Regeneration, Department of Oral Implantology, School of Stomatology, Tongji University, Shanghai
| | - Jiafan Liu
- Department of Cell Biology, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China
| | - Yao Sun
- Engineering Research Center of Tooth Restoration and Regeneration, Department of Oral Implantology, School of Stomatology, Tongji University, Shanghai
| | - Xiaogang Wang
- Department of Cell Biology, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China
| |
Collapse
|
60
|
NLRC5 promotes cell proliferation via regulating the NF-κB signaling pathway in Rheumatoid arthritis. Mol Immunol 2017; 91:24-34. [PMID: 28865311 DOI: 10.1016/j.molimm.2017.08.024] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 08/24/2017] [Accepted: 08/26/2017] [Indexed: 12/23/2022]
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease and the pathogenesis remains unclear. Previous studies suggested that fibroblast-like synoviocytes (FLSs) play an important role in RA pathogenesis, including the injury of cartilage, the hyperplasia of the synovium and the release of inflammatory cytokines. We used complete Freund's adjuvant (CFA) induced rats as animal models for studying the RA pathogenesis. NLRC5 as the largest member of the NLR family has been reported to play a critical role in regulating immune responses. Increasing evidence suggests that NLRC5 is an pivotal negative modulator of inflammatory pathways. We investigated the mechanisms and signaling pathways of NLRC5 in RA progression. Significantly increased expression of NLRC5 was found in AA rats synovial tissues and cells. And high expression of inflammatory cytokine and cell proliferation of FLSs accompanied with NLRC5 overexpression, but inhibited in cells with NLRC5 silencing treatment. Interestingly, we found that overexpression of NLRC5 also coordinated the activation of NF-κB signaling pathway. These results suggested that NLRC5 promotes RA progression via the NF-κB signaling pathway potentially.
Collapse
|
61
|
Mbalaviele G, Novack DV, Schett G, Teitelbaum SL. Inflammatory osteolysis: a conspiracy against bone. J Clin Invest 2017; 127:2030-2039. [PMID: 28569732 DOI: 10.1172/jci93356] [Citation(s) in RCA: 155] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
There are many causes of inflammatory osteolysis, but regardless of etiology and cellular contexts, the osteoclast is the bone-degrading cell. Thus, the impact of inflammatory cytokines on osteoclast formation and function was among the most important discoveries advancing the treatment of focal osteolysis, leading to development of therapeutic agents that either directly block the bone-resorptive cell or do so indirectly via cytokine arrest. Despite these advances, a substantial number of patients with inflammatory arthritis remain resistant to current therapies, and even effective anti-inflammatory drugs frequently do not repair damaged bone. Thus, insights into events such as those impacted by inflammasomes, which signal through cytokine-dependent and -independent mechanisms, are needed to optimize treatment of inflammatory osteolysis.
Collapse
Affiliation(s)
| | - Deborah V Novack
- Department of Medicine, Division of Bone and Mineral Diseases, and.,Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Georg Schett
- Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
| | - Steven L Teitelbaum
- Department of Medicine, Division of Bone and Mineral Diseases, and.,Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine, St. Louis, Missouri, USA
| |
Collapse
|
62
|
Wang Q, Jiang H, Li Y, Chen W, Li H, Peng K, Zhang Z, Sun X. Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy. Biomaterials 2017; 122:10-22. [DOI: 10.1016/j.biomaterials.2017.01.008] [Citation(s) in RCA: 120] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 01/04/2017] [Accepted: 01/07/2017] [Indexed: 12/17/2022]
|
63
|
Antimisiaris S, Mourtas S, Papadia K. Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential. Int J Pharm 2017; 525:293-312. [PMID: 28163221 DOI: 10.1016/j.ijpharm.2017.01.056] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 01/25/2017] [Accepted: 01/27/2017] [Indexed: 12/17/2022]
Abstract
The concept of RNA interference therapeutics has been initiated 18 years ago, and the main bottleneck for translation of the technology into therapeutic products remains the delivery of functional RNA molecules into the cell cytoplasm. In the present review article after an introduction about the theoretical basis of RNAi therapy and the main challenges encountered for its realization, an overview of the different types of delivery systems or carriers, used as potential systems to overcome RNAi delivery issues, will be provided. Characteristic examples or results obtained with the most promising systems will be discussed. Focus will be given mostly on the applications of liposomes or other types of lipid carriers, such as exosomes, towards improved delivery of RNAi to therapeutic targets. Finally the approach of integrating the advantages of these two vesicular systems, liposomes and exosomes, as a potential solution to realize RNAi therapy, will be proposed.
Collapse
Affiliation(s)
- Sophia Antimisiaris
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26504, Greece; Institute of Chemical Engineering, FORTH/ICE-HT, Rio 26504, Greece.
| | - Spyridon Mourtas
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26504, Greece
| | - Konstantina Papadia
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26504, Greece
| |
Collapse
|
64
|
Abstract
Schematic illustration of inflammatory microenvironment in inflamed joints and events occurring in rheumatoid arthritis.
Collapse
Affiliation(s)
- Qin Wang
- Key Laboratory of Drug Targeting and Drug Delivery Systems
- Ministry of Education
- West China School of Pharmacy
- Sichuan University
- Chengdu
| | - Xun Sun
- Key Laboratory of Drug Targeting and Drug Delivery Systems
- Ministry of Education
- West China School of Pharmacy
- Sichuan University
- Chengdu
| |
Collapse
|
65
|
Zhu Q, Huang J, Wang SZ, Qin ZH, Lin F. Cobrotoxin extracted from Naja atra venom relieves arthritis symptoms through anti-inflammation and immunosuppression effects in rat arthritis model. JOURNAL OF ETHNOPHARMACOLOGY 2016; 194:1087-1095. [PMID: 27840083 DOI: 10.1016/j.jep.2016.11.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/20/2016] [Revised: 10/31/2016] [Accepted: 11/04/2016] [Indexed: 06/06/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE The Naja atra (Chinese cobra), primarily distributing in the low or medium altitude areas of southern China and Taiwan, was considered as a medicine in traditional Chinese medicine and used to treat pain, inflammation and arthritis. AIM OF THE STUDY To study the anti-inflammatory and anti-arthritic activities of cobrotoxin (CTX), an active component of the venom from Naja atra. MATERIALS AND METHODS Adjuvant-induced arthritis (AA) rats were used as the animal model of rheumatoid arthritis. The anti-arthritic effects of CTX were evaluated through the arthritis score, paw edema and histopathology changes of joints. The anti-inflammation effects were assayed by the level of IL-6, TNF-α, IL-1β and the number of inflammatory cells in peripheral blood, as well as the proliferation of fibroblast-like synoviocytes (FLS). The immune level was valued by the proliferation of T cells and the level of CD4 and CD8. RESULTS CTX alleviated the disease development of AA rats according to the ameliorating arthritis score, paw edema and histopathology character. At the meanwhile, CTX decreased the levels of IL-6, TNF-α, IL-1β and the numbers of inflammatory cells in peripheral blood. CTX also suppressed the abnormal increasing of CD4+ T cells/ CD8+ T cells ratio, and could significantly inhibit T cell proliferation. Consistent with its effects on inhibiting granuloma's formation, CTX inhibited the proliferation of the cultured FLSs. Further studies on inflammatory signaling in FLSs revealed that CTX could inhibit the NF-κB signaling pathway. CONCLUSIONS CTX has beneficial effects on rheumatoid arthritis by its immune regulation effects and anti-inflammation effects. The inhibition of NF-κB pathway partly contributes to the anti-inflammatory properties of CTX.
Collapse
Affiliation(s)
- Qi Zhu
- Department of Pharmacology, Laboratory of Aging and Nervous Diseases (SZS0703), Soochow University School of Pharmaceutical Science, Su Zhou 215123, China..
| | - Jun Huang
- Department of Pharmacology, Laboratory of Aging and Nervous Diseases (SZS0703), Soochow University School of Pharmaceutical Science, Su Zhou 215123, China..
| | - Shu-Zhi Wang
- Department of Pharmacology, Laboratory of Aging and Nervous Diseases (SZS0703), Soochow University School of Pharmaceutical Science, Su Zhou 215123, China..
| | - Zheng-Hong Qin
- Department of Pharmacology, Laboratory of Aging and Nervous Diseases (SZS0703), Soochow University School of Pharmaceutical Science, Su Zhou 215123, China..
| | - Fang Lin
- Department of Pharmacology, Laboratory of Aging and Nervous Diseases (SZS0703), Soochow University School of Pharmaceutical Science, Su Zhou 215123, China..
| |
Collapse
|
66
|
Lozhkin A, Vendrov AE, Pan H, Wickline SA, Madamanchi NR, Runge MS. NADPH oxidase 4 regulates vascular inflammation in aging and atherosclerosis. J Mol Cell Cardiol 2016; 102:10-21. [PMID: 27986445 PMCID: PMC5625334 DOI: 10.1016/j.yjmcc.2016.12.004] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Revised: 12/08/2016] [Accepted: 12/12/2016] [Indexed: 01/10/2023]
Abstract
We recently reported that increased NADPH oxidase 4 (NOX4) expression and activity during aging results in enhanced cellular and mitochondrial oxidative stress, vascular inflammation, dysfunction, and atherosclerosis. The goal of the present study was to elucidate the molecular mechanism(s) for these effects and determine the importance of NOX4 modulation of proinflammatory gene expression in mouse vascular smooth muscle cells (VSMCs). A novel peptide-mediated siRNA transfection approach was used to inhibit Nox4 expression with minimal cellular toxicity. Using melittin-derived peptide p5RHH, we achieved significantly higher transfection efficiency (92% vs. 85% with Lipofectamine) and decreased toxicity (p<0.001 vs. Lipofectamine in MTT and p<0.0001 vs. Lipofectamine in LDH assays) in VSMCs. TGFβ1 significantly upregulates Nox4 mRNA (p<0.01) and protein (p<0.01) expression in VSMCs. p5RHH-mediated Nox4 siRNA transfection greatly attenuated TGFβ1-induced upregulation of Nox4 mRNA (p<0.01) and protein (p<0.0001) levels and decreased hydrogen peroxide production (p<0.0001). Expression of pro-inflammatory genes Ccl2, Ccl5, Il6, and Vcam1 was significantly upregulated in VSMCs in several settings cells isolated from aged vs. young wild-type mice, in atherosclerotic arteries of Apoe-/- mice, and atherosclerotic human carotid arteries and correlated with NOX4 expression. p5RHH-mediated Nox4 siRNA transfection significantly attenuated the expression of these pro-inflammatory genes in TGFβ1-treated mouse VSMCs, with the highest degree of inhibition in the expression of Il6. p5RHH peptide-mediated knockdown of TGFβ-activated kinase 1 (TAK1, also known as Map3k7), Jun, and Rela, but not Nfkb2, downregulated TGFβ1-induced Nox4 expression in VSMCs. Together, these data demonstrate that increased expression and activation of NOX4, which might result from increased TGFβ1 levels seen during aging, induces a proinflammatory phenotype in VSMCs, enhancing atherosclerosis.
Collapse
Affiliation(s)
- Andrey Lozhkin
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor 48109, MI, USA
| | - Aleksandr E Vendrov
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor 48109, MI, USA
| | - Hua Pan
- Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis 63110, MO, USA
| | - Samuel A Wickline
- Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis 63110, MO, USA
| | - Nageswara R Madamanchi
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor 48109, MI, USA
| | - Marschall S Runge
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor 48109, MI, USA.
| |
Collapse
|
67
|
Systemic delivery of small interfering RNA targeting nuclear factor κB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles. Int J Pharm 2016; 515:315-323. [DOI: 10.1016/j.ijpharm.2016.10.033] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Revised: 09/23/2016] [Accepted: 10/16/2016] [Indexed: 01/15/2023]
|
68
|
Suppression of NF-κB activity via nanoparticle-based siRNA delivery alters early cartilage responses to injury. Proc Natl Acad Sci U S A 2016; 113:E6199-E6208. [PMID: 27681622 PMCID: PMC5068304 DOI: 10.1073/pnas.1608245113] [Citation(s) in RCA: 100] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Osteoarthritis (OA) is a major cause of disability and morbidity in the aging population. Joint injury leads to cartilage damage, a known determinant for subsequent development of posttraumatic OA, which accounts for 12% of all OA. Understanding the early molecular and cellular responses postinjury may provide targets for therapeutic interventions that limit articular degeneration. Using a murine model of controlled knee joint impact injury that allows the examination of cartilage responses to injury at specific time points, we show that intraarticular delivery of a peptidic nanoparticle complexed to NF-κB siRNA significantly reduces early chondrocyte apoptosis and reactive synovitis. Our data suggest that NF-κB siRNA nanotherapy maintains cartilage homeostasis by enhancing AMPK signaling while suppressing mTORC1 and Wnt/β-catenin activity. These findings delineate an extensive crosstalk between NF-κB and signaling pathways that govern cartilage responses postinjury and suggest that delivery of NF-κB siRNA nanotherapy to attenuate early inflammation may limit the chronic consequences of joint injury. Therapeutic benefits of siRNA nanotherapy may also apply to primary OA in which NF-κB activation mediates chondrocyte catabolic responses. Additionally, a critical barrier to the successful development of OA treatment includes ineffective delivery of therapeutic agents to the resident chondrocytes in the avascular cartilage. Here, we show that the peptide-siRNA nanocomplexes are nonimmunogenic, are freely and deeply penetrant to human OA cartilage, and persist in chondrocyte lacunae for at least 2 wk. The peptide-siRNA platform thus provides a clinically relevant and promising approach to overcoming the obstacles of drug delivery to the highly inaccessible chondrocytes.
Collapse
|
69
|
Wang YL, Gao JM, Xing LZ. Therapeutic potential of Oroxylin A in rheumatoid arthritis. Int Immunopharmacol 2016; 40:294-299. [PMID: 27643663 DOI: 10.1016/j.intimp.2016.09.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Revised: 08/26/2016] [Accepted: 09/06/2016] [Indexed: 12/20/2022]
Abstract
Excessive inflammation contributes greatly to the pathogenesis and development of rheumatoid arthritis (RA). Oroxylin A (OA) is a natural anti-inflammatory flavonoid compound. In this study, we investigated the effects of OA on collagen-induced arthritis (CIA) and human RA fibroblast-like synoviocytes (FLS). CIA was induced in DBA/1 mice and mice were intraperitoneally treated with OA (10mg/kg) for 10days. Arthritis severity was evaluated every day and the histopathologic examination of joints was done. Serum levels of anti-collagen II antibodies (anti-CII Abs) and cytokines were determined by ELISA. Frequency of regulatory T cells (Tregs) and Th17 cells in draining inguinal lymph nodes (ILN) was quantified by flow cytometry. FLS from patients with active RA were treated with varying doses of oroxylin A, followed by stimulation with tumor necrosis factor (TNF)-α (10ng/mL). The production of cytokines was measured by ELISA. Signal transduction proteins were examined by western blot. OA significantly diminished the arthritis and histological damage. Serum anti-CII Abs, IL-1β, IL-6, TNFα, and IL-17 were significantly diminished by OA treatment. Analysis of CD4+T cell populations in OA-treated mice showed an increase in Tregs and reduction in Th17 cells in the ILN. In vitro, OA decreased the secretion of IL-1β and IL-6 from TNFα-stimulated RA FLS in a dose-dependent manner. TNFα-induced p38 MAPK, ERK1/2 and NF-κB signaling pathways were suppressed by OA. Our results indicate that OA exerts an anti-inflammatory activity and may have therapeutic potential for human RA.
Collapse
Affiliation(s)
- Yu-Ling Wang
- Department of Rheumatology and Immunology, Linyi People's Hospital, Linyi 276003, Shandong, China
| | - Ju-Mei Gao
- Department of Rheumatology and Immunology, Yishui Central Hospital, Linyi 276400, Shandong, China
| | - Li-Zhi Xing
- Department of Endocrinology, Linyi People's Hospital, Linyi 276003, Shandong, China.
| |
Collapse
|
70
|
Sun Y, Ye X, Cai M, Liu X, Xiao J, Zhang C, Wang Y, Yang L, Liu J, Li S, Kang C, Zhang B, Zhang Q, Wang Z, Hong A, Wang X. Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery. ACS NANO 2016; 10:5759-68. [PMID: 27176123 DOI: 10.1021/acsnano.5b07828] [Citation(s) in RCA: 106] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Antiosteoporosis gene-based drug development strategies are presently focused on targeting osteoblasts to either suppress bone loss or increase bone mass. Although siRNA/microRNA-based gene therapy has enormous potential, it is severely limited by the lack of specific cell-targeting delivery systems. We report an osteoblast-targeting peptide (SDSSD) that selectively binds to osteoblasts via periostin. We developed SDSSD-modified polyurethane (PU) nanomicelles encapsulating siRNA/microRNA that delivers drugs to osteoblasts; the data showed that SDSSD-PU could selectively target not only bone-formation surfaces but also osteoblasts without overt toxicity or eliciting an immune response in vivo. We used the SDSSD-PU delivery system to deliver anti-miR-214 to osteoblasts and our results showed increased bone formation, improved bone microarchitecture, and increased bone mass in an ovariectomized osteoporosis mouse model. SDSSD-PU may be a useful osteoblast-targeting small nucleic acid delivery system that could be used as an anabolic strategy to treat osteoblast-induced bone diseases.
Collapse
Affiliation(s)
- Yao Sun
- Department of Oral Implantology, School of Stomatology, Tongji University , Shanghai 200072, China
- Shanghai Engineering Research Center of Tooth Restoration and Regeneration , Shanghai 200072, China
- Sino-Russian Institute of Hard Tissue Development and Regeneration, The Second Affiliated Hospital of Harbin Medical University , Harbin 150086, China
| | - Xiongzhen Ye
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| | - Mingxiang Cai
- Department of Oral Implantology, School of Stomatology, Tongji University , Shanghai 200072, China
| | - Xiangning Liu
- The First Affiliated Hospital of Jinan University , Guangzhou 510632, China
| | - Jia Xiao
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| | - Chenyang Zhang
- Department of Oral Implantology, School of Stomatology, Tongji University , Shanghai 200072, China
| | - Yayu Wang
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| | - Li Yang
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| | - Jiafan Liu
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| | - Shannai Li
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| | - Chen Kang
- Sino-Russian Institute of Hard Tissue Development and Regeneration, The Second Affiliated Hospital of Harbin Medical University , Harbin 150086, China
| | - Bin Zhang
- Sino-Russian Institute of Hard Tissue Development and Regeneration, The Second Affiliated Hospital of Harbin Medical University , Harbin 150086, China
| | - Qi Zhang
- Department of Oral Implantology, School of Stomatology, Tongji University , Shanghai 200072, China
| | - Zuolin Wang
- Department of Oral Implantology, School of Stomatology, Tongji University , Shanghai 200072, China
- Shanghai Engineering Research Center of Tooth Restoration and Regeneration , Shanghai 200072, China
| | - An Hong
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| | - Xiaogang Wang
- Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University , Guangzhou 510632, China
| |
Collapse
|
71
|
Jakkampudi A, Jangala R, Reddy BR, Mitnala S, Nageshwar Reddy D, Talukdar R. NF-κB in acute pancreatitis: Mechanisms and therapeutic potential. Pancreatology 2016; 16:477-88. [PMID: 27282980 DOI: 10.1016/j.pan.2016.05.001] [Citation(s) in RCA: 101] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Revised: 05/03/2016] [Accepted: 05/04/2016] [Indexed: 12/11/2022]
Abstract
The incidence of acute pancreatitis (AP) is increasing globally and mortality could be high among patients with organ failure and infected necrosis. The predominant factors responsible for the morbidity and mortality of AP are systemic inflammatory response syndrome and multiorgan dysfunction. Even though preclinical studies have shown antisecretory agents (somatostatin), antioxidants (S-adenosyl methionine [SAM], selenium), protease inhibitors, platelet activating factor inhibitor (Lexipafant), and anti-inflammatory immunomodulators (eg. prostaglandin E, indomethacin) to benefit AP in terms of reducing the severity and/or mortality, most of these agents have shown heterogeneous results in clinical studies. Several years of experimental studies have implicated nuclear factor-kappa B (NF-κB) activation as an early and central event in the progression of inflammation in AP. In this manuscript, we review the literature on the role of NF-κB in the pathogenesis of AP, its early intraacinar activation, and how it results in progression of the disease. We also discuss why anti-protease, antisecretory, and anti-inflammatory agents are unlikely to be effective in clinical acute pancreatitis. NF-κB, being a central molecule that links the initial acinar injury to systemic inflammation and perpetuate the inflammation, we propose that more studies be focussed towards targeted inhibition of NF-κB activity. Direct NF-κB inhibition strategies have already been attempted in patients with various cancers. So far, peroxisome proliferator activator receptor gamma (PPAR-γ) ligand, pyrrolidine dithiocarbamate (PDTC), proteasome inhibitor and calpain I inhibitor have been shown to have direct inhibitory effects on NF-κB activation in experimental AP.
Collapse
Affiliation(s)
- Aparna Jakkampudi
- Wellcome-DBT Laboratory, Asian Healthcare Foundation, Hyderabad, India
| | - Ramaiah Jangala
- Wellcome-DBT Laboratory, Asian Healthcare Foundation, Hyderabad, India
| | - B Ratnakar Reddy
- Wellcome-DBT Laboratory, Asian Healthcare Foundation, Hyderabad, India
| | - Sasikala Mitnala
- Wellcome-DBT Laboratory, Asian Healthcare Foundation, Hyderabad, India
| | - D Nageshwar Reddy
- Dept. of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India
| | - Rupjyoti Talukdar
- Wellcome-DBT Laboratory, Asian Healthcare Foundation, Hyderabad, India; Dept. of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
| |
Collapse
|
72
|
Targeted delivery of low-dose dexamethasone using PCL–PEG micelles for effective treatment of rheumatoid arthritis. J Control Release 2016; 230:64-72. [DOI: 10.1016/j.jconrel.2016.03.035] [Citation(s) in RCA: 141] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 03/17/2016] [Accepted: 03/28/2016] [Indexed: 11/21/2022]
|
73
|
Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res 2016; 44:6518-48. [PMID: 27084936 PMCID: PMC5001581 DOI: 10.1093/nar/gkw236] [Citation(s) in RCA: 567] [Impact Index Per Article: 70.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Accepted: 03/28/2016] [Indexed: 12/14/2022] Open
Abstract
The oligonucleotide therapeutics field has seen remarkable progress over the last few years with the approval of the first antisense drug and with promising developments in late stage clinical trials using siRNA or splice switching oligonucleotides. However, effective delivery of oligonucleotides to their intracellular sites of action remains a major issue. This review will describe the biological basis of oligonucleotide delivery including the nature of various tissue barriers and the mechanisms of cellular uptake and intracellular trafficking of oligonucleotides. It will then examine a variety of current approaches for enhancing the delivery of oligonucleotides. This includes molecular scale targeted ligand-oligonucleotide conjugates, lipid- and polymer-based nanoparticles, antibody conjugates and small molecules that improve oligonucleotide delivery. The merits and liabilities of these approaches will be discussed in the context of the underlying basic biology.
Collapse
Affiliation(s)
- Rudolph L Juliano
- UNC Eshelman School of Pharmacy and UNC School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
| |
Collapse
|
74
|
Hou KK, Pan H, Schlesinger PH, Wickline SA. A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin. Biotechnol Adv 2015; 33:931-40. [PMID: 26025036 PMCID: PMC4540690 DOI: 10.1016/j.biotechadv.2015.05.005] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 05/20/2015] [Accepted: 05/23/2015] [Indexed: 12/21/2022]
Abstract
siRNA has the possibility to revolutionize medicine by enabling highly specific and efficient silencing of proteins involved in disease pathogenesis. Despite nearly 20 years of research dedicated to translating siRNA from a research tool into a clinically relevant therapeutic, minimal success has been had to date. Access to RNA interference machinery located in the cytoplasm is often overlooked, but must be considered when designing the next generation of siRNA delivery strategies. Peptide transduction domains (PTDs) have demonstrated moderate siRNA transfection, which is primarily limited by endosomal entrapment. Strategies aimed at overcoming endosomal entrapment associated with peptide vectors are reviewed here, including osmotic methods, lipid conjugation, and fusogenic peptides. As an alternative to traditional PTD, the hemolytic peptide melittin exhibits the native capacity for endosomal disruption but causes cytotoxicity. However, appropriate packaging and protection of melittin with activation and release in the endosomal compartment has allowed melittin-based strategies to demonstrate both in vitro and in vivo safety and efficacy. These data suggest that melittin's membrane disruptive properties can enable safe and effective endosomolysis, building a case for melittin as a key component in a new generation of siRNA therapeutics.
Collapse
Affiliation(s)
- Kirk K Hou
- Computational and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63108, USA
| | - Hua Pan
- Department of Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
| | - Paul H Schlesinger
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63108, USA
| | - Samuel A Wickline
- Department of Medicine, Washington University School of Medicine, St Louis, MO 63108, USA; Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63108, USA; Department of Biomedical Engineering, Washington University School of Medicine, St. Louis, MO 63108, USA.
| |
Collapse
|
75
|
Guo J, McKenna SL, O’Dwyer ME, Cahill MR, O’Driscoll CM. RNA interference for multiple myeloma therapy: targeting signal transduction pathways. Expert Opin Ther Targets 2015; 20:107-21. [DOI: 10.1517/14728222.2015.1071355] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
76
|
Pham CT, Pan H, Wickline SA. Peptide-siRNA nanotherapeutics in arthritis. Oncotarget 2015; 6:14731-2. [PMID: 26142704 PMCID: PMC4558109 DOI: 10.18632/oncotarget.4439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
77
|
Jallouk AP, Palekar RU, Pan H, Schlesinger PH, Wickline SA. Modifications of natural peptides for nanoparticle and drug design. ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY 2015; 98:57-91. [PMID: 25819276 PMCID: PMC4750874 DOI: 10.1016/bs.apcsb.2014.12.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Natural products serve as an important source of novel compounds for drug development. Recently, peptides have emerged as a new class of therapeutic agents due to their versatility and specificity for biological targets. Yet, their effective application often requires use of a nanoparticle delivery system. In this chapter, we review the role of natural peptides in the design and creation of nanomedicines, with a particular focus on cell-penetrating peptides, antimicrobial peptides, and peptide toxins. The use of natural peptides in conjunction with nanoparticle delivery systems holds great promise for the development of new therapeutic formulations as well as novel platforms for the delivery of various cargoes.
Collapse
Affiliation(s)
- Andrew P. Jallouk
- Consortium for Translational Research in Advanced Imaging and Nanomedicine, Department of Medicine, Division of Cardiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108
| | - Rohun U. Palekar
- Consortium for Translational Research in Advanced Imaging and Nanomedicine, Department of Medicine, Division of Cardiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108
| | - Hua Pan
- Consortium for Translational Research in Advanced Imaging and Nanomedicine, Department of Medicine, Division of Cardiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108
| | - Paul H. Schlesinger
- Department of Cell Biology and Physiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110
| | - Samuel A. Wickline
- Consortium for Translational Research in Advanced Imaging and Nanomedicine, Department of Medicine, Division of Cardiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108
- Department of Cell Biology and Physiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110
| |
Collapse
|
78
|
Ferrari M, Onuoha SC, Pitzalis C. Trojan horses and guided missiles: targeted therapies in the war on arthritis. Nat Rev Rheumatol 2015; 11:328-37. [DOI: 10.1038/nrrheum.2015.17] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|